Fatigue in patients with lung cancer is related with accelerated tryptophan breakdown

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Kurz, Katharina ^a   Fiegl, Michael ^a   Holzner, Bernhard ^a   Giesinger, Johannes ^b   Pircher, Marianna ^b   Weiss, Guenter ^a   Denz, Hubert A ^b   Fuchs, Dietmar ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Hospital Natters   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; HEMOGLOBIN; KYNURENINE; NEOPTERIN; TRYPTOPHAN;

AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ANEMIA; ARTICLE; CANCER FATIGUE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; COPING BEHAVIOR; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EASTERN COOPERATIVE ONCOLOGY GROUP SCORE; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY ANEMIA SCORE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY FATIGUE SCORE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOREACTIVITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MENTAL ADJUSTMENT TO CANCER QUESTIONNAIRE; PATHOGENESIS; PATIENT ATTITUDE; PHYSICAL PERFORMANCE; PROTEIN DEGRADATION; PSYCHOLOGIC TEST; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SELF EVALUATION;

ANEMIA; FATIGUE; FEMALE; HUMANS; INFLAMMATION; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PSYCHOLOGICAL TESTS; QUALITY OF LIFE; TRYPTOPHAN; TUMOR MARKERS, BIOLOGICAL;

EID: 84861215693     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036956     Document Type: Article

References (57)

1. Portenoy RK, (2000) Cancer-related fatigue: An immense problem. Oncologist 5: 350-352.
2. Curt GA, (2000) Impact of fatigue on quality of life in oncology patients. Semin Hematol 37: 14-17.
3. Curt GA, (2000) The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncologist 5 (Suppl 2): 9-12.
4. Baile WF, (1996) Neuropsychiatric disorders in cancer patients. Curr Opin Oncol 8: 182-187.
5. Carr D, Goudas L, Lawrence D, Pirl W, Lau J, et al. (2002) Management of cancer symptoms: pain, depression, and fatigue. Evid Rep Technol Assess pp. 1-5.
6. Spiegel D, Giese-Davis J, (2003) Depression and cancer: mechanisms and disease progression. Biol Psychiatry 54: 269-282.
7. Pirl WF, (2004) Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr 32-39.
8. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, et al. (2005) Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 58: 175-189.
9. Stone P, Richards M, Hardy J, (1998) Fatigue in patients with cancer. Eur J Cancer 34: 1670-1676.
10. Hickok JT, Morrow GR, McDonald S, Bellg AJ, (1996) Frequency and correlates of fatigue in lung cancer patients receiving radiation therapy: implications for management. J Pain Symptom Managem 11: 370-377.
11. Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, et al. (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey- The Fatigue Coalition. Semin Hematol 34: 4-12-.
12. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, et al. (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5: 353-360.
13. Portenoy RK, Itri LM, (1999) Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4: 1-10.
14. Weiss G, Goodnough LT, (2005) Anemia of chronic disease. N Engl J Med 352: 1011-1023.
15. Visser MR, Smets EM, (1998) Fatigue, depression and quality of life in cancer patients: how are they related? Support Care Cancer 6: 101-108.
16. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, et al. (2000) Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 18: 743-753.
17. Bower JE, Ganz PA, Aziz N, Fahey JL, (2002) Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 64: 604-611.
18. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, et al. (1991) Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol 294: 425-435.
19. Murr C, Widner B, Sperner-Unterweger B, Ledochowski M, Schubert C, et al. (2000) Immune reaction links disease progression in cancer patients with depression. Med Hypotheses 55: 137-40.
20. Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, et al. (2000) Illness, cytokines, and depression. Ann N Y Acad Sci 917: 478-487.
21. Kurzrock R, (2001) The role of cytokines in cancer-related fatigue. Cancer 92: 1684-1688.
22. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR, (2008) Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 26: 971-982.
23. Dantzer R, (2001) Cytokine-induced sickness behavior: mechanisms and implications. Ann NY Acad Sci 933: 222-234.
24. Widner B, Laich A, Sperner-Unterweger B, Ledochowski M, Fuchs D, (2002) Neopterin production, tryptophan degradation, and mental depression- what is the link? Brain Behav Immun 16: 590-595.
25. Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, et al. (2003) Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97: 2919-2925.
26. Dantzer R, O'Connor JC, Lawson MA, Kelley KW, (2011) Inflammation associated depression: From serotonin to kynurenine. Psychoneuroendocrinology 36: 426-436.
27. Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, et al. (1989) Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2, 3-dioxygenase activity in human cells and cell lines by interferon-gamma. Biochem J 262: 861-866.
28. Taylor MW, Feng GS, (1991) Relationship between interferon-gamma, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J 5: 2516-2522.
29. Schroecksnadel K, Wirleitner B, Winkler C, Fuchs D, (2006) Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 364: 82-90.
30. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, et al. (1984) Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 160: 310-316.
31. Denz H, Orth B, Weiss G, Herrmann R, Huber P, et al. (1993) Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clin Investig 71: 37-41.
32. Iwagaki H, Hizuta A, Tanaka N, Orita K, (1995) Decreased serum tryptophan in patients with cancer cachexia correlates with increased serum neopterin. Immunol Investig 24: 467-478.
33. Huang A, Fuchs D, Widner B, Glover C, Henderson DC, et al. (2002) Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 86: 1691-1696.
34. Schroecksnadel K, Winkler C, Fuith LC, Fuchs D, (2005) Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett 223: 323-329.
35. Schroecksnadel K, Fiegl M, Prassl K, Winkler C, Denz HA, et al. (2007) Diminished quality of life in patients with cancer correlates with tryptophan degradation. J Cancer Res Clin Oncol 133: 477-485.
36. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E, (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Managem 13: 63-74.
37. Watson M, Greer S, Young J, Inayat Q, Burgess C, et al. (1988) Development of a questionnaire measure of adjustment to cancer: the MAC scale. Psychol Med 18: 203-209.
38. Watson M, Homewood J, (2008) Mental Adjustment to Cancer Scale: psychometric properties in a large cancer cohort. Psychooncology 17: 1146-1151.
39. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D, (1997) Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 43: 2424-2426.
40. Fuchs D, Moeller AA, Reibnegger G, Werner ER, Werner-Felmayer G, et al. (1991) Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett 28: 207-211.
41. Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, et al. (1990) Immune activation and the anaemia associated with chronic inflammatory disorders. Eur J Haematol 46: 65-70.
42. Fuchs D, Zangerle R, Artner-Dworzak E, Weiss G, Fritsch P, et al. (1993) Association between immune activation, changes of iron metabolism and anaemia in patients with HIV infection. Eur J Haematol 50: 90-4.
43. Sarcletti M, Quirchmair G, Weiss G, Fuchs D, Zangerle R, (2003) Increase of haemoglobin levels by anti-retroviral therapy is associated with a decrease in immune activation. Eur J Haematol 70: 17-25.
44. Weiss G, Schroecksnadel K, Mattle V, Winkler C, Konwalinka G, et al. (2004) Possible role of cytokine-induced tryptophan degradation in anemia of inflammation. Eur J Haematol 72: 130-134.
45. Holzner B, Kemmler G, Greil R, Kopp M, Zeimet A, et al. (2002) The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 13: 965-973.
46. Hayes JR, (1991) Depression and chronic fatigue in cancer patients. Primary Care 18: 327-339.
47. Schroecksnadel K, Scarletti M, Winkler C, Mumelter B, Weiss G, et al. (2008) Quality of life and immune activation in patients with HIV-infection. Brain Behav Immun 22: 881-889.
48. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, et al. (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115: 1249-73.
49. Chiarugi A, Meli E, Moroni F, (2001) Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid. J Neurochem 77: 1310-8.
50. Moroni F, Russi P, Lombardi G, Beni M, Carlà V, (1988) Presence of kynurenic acid in the mammalian brain. J Neurochem 51: 177-80.
51. Chen Y, Guillemin GJ, (2009) Kynurenine pathway metabolites in humans: disease and healthy States. Int J Tryptophan Res 2: 1-19.
52. Dantzer R, O'Connor JC, Lawson MA, Kelley KW, (2011) Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36: 426-36.
53. Myint AM, (2012) Kynurenines: From the perspective of major psychiatric disorders. FEBS J- epub ahead of print.
54. O' Connor JC, Lawson MA, André C, Briley EM, Szegedi SS, et al. (2009) Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior. J Immunol 182: 3202-3212.
55. Capuron L, Schroecksnadel S, Féart C, Aubert A, Higueret D, et al. (2011) Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 70: 175-82.
56. Neurauter G, Schröcksnadel K, Scholl-Bürgi S, Sperner-Unterweger B, Schubert C, et al. (2008) Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab 9: 622-627.
57. Thornton LM, Andersen BL, Schuler TA, Carson WE 3rd, (2009) A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial. Psychosom Med 71: 715-724.